Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 May 6.

Published in final edited form as: Kidney Int. 2020 Jun 14;98(5):1308–1322. doi: 10.1016/j.kint.2020.05.029

Figure 4. — (A) NPHS1 fragments per kilobase million (FPKM) expression comparing samples withand without NPHS1 risk haplotype. Samples with the NPHS1 risk haplotype do not show significantly different expression levels (Wilcox test p=0.39).

(B) Allele-specific expression (ASE) comparing samples with and without NPHS1 risk haplotype. ASE = |0.5 − (haplotype A / total reads)|. In patients with the risk alleles, haplotype A harbors all five NPHS1 risk variants, in patients without the risk haplotype, haplotype A is randomly selected from one of their two haplotypes. Sample with less than two heterozygous SNPs or in the bottom 10% of total counts are indicated in gray. Samples with the NPHS1 risk haplotype show significant allele specific expression with lower expression of the risk haplotype (Wilcox test p=9.3E-4).

Figure 4. — (A) NPHS1 fragments per kilobase million (FPKM) expression comparing samples withand without NPHS1 risk haplotype. Samples with the NPHS1 risk haplotype do not show significantly different expression levels (Wilcox test p=0.39).

(B) Allele-specific expression (ASE) comparing samples with and without NPHS1 risk haplotype. ASE = |0.5 − (haplotype A / total reads)|. In patients with the risk alleles, haplotype A harbors all five NPHS1 risk variants, in patients without the risk haplotype, haplotype A is randomly selected from one of their two haplotypes. Sample with less than two heterozygous SNPs or in the bottom 10% of total counts are indicated in gray. Samples with the NPHS1 risk haplotype show significant allele specific expression with lower expression of the risk haplotype (Wilcox test p=9.3E-4).